Patient description: A 45-year-old woman was referred to the emergency department with abdominal pain lasting about 4 days accompanied by nausea and 2 episodes of vomiting. The pain is localized to the epigastric region and radiates to the right upper quadrant. The pain is worsening after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and two C/sections. She has 2 children, and she is menopausal. She doesn't smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones and biliary sludge. The largest gallstone is 0.7cm. Surgery consultation recommends elective cholecystectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Patients With Dyspeptic Symptoms After Cholecystectomy Aged 18-70 years old, male or female; 2. Patients after laparoscopic cholecystectomy, mainly including cholecystectomy due to cholecystitis, gallstones, gallbladder polyps and other benign gallbladder tumors, non-functioning gallbladder; 3. Dyspeptic symptoms occurred 2 weeks after laparoscopic cholecystectomy, including: abdominal distension, abdominal pain/abdominal discomfort, diarrhea/fatty stool, early satiety, belching, loss of appetite; 4. Signed informed consent, agreed to participate in this study  Patients with abnormal liver function and renal function; 2. Patients with severe heart and lung dysfunction; 3. Patients with neurological, mental illness or other reasons can not cooperate with the study; 4. Patients with advanced malignant tumors or other serious wasting diseases, any unstable chronic diseases and acute diseases, interfere with the efficacy evaluation of this study (such as patients undergoing chemotherapy) and the completion of the trial plan; 5. Patients with biliary obstruction, acute hepatitis, etc., do not use the test drugs and control drugs, and allergic to the test drugs and control drugs; 6. Patients who have taken digestive enzymes and cholagogue drugs by themselves; 7. Pregnant and lactating women; 8. Patients who are participating in other clinical trials; 9. Patients who cannot be followed up on time. Elimination 1. Failure to take medicine as required, that is,Failure to take medicine or missed doses ≥ 3 times within 1week; 2. Taking other digestive enzymes, cholagogues and prokinetic drugs or drugs affecting digestive enzymes and bile secretion and excretion during the study; 3. Adverse events occur, for the benefit of patients, doctors believe that the drug should not be continued; the results of such cases do not participate in the efficacy statistics, but are related to the safety evaluation. Drop-out 1. Cases with adverse events and patients are not willing to continue participating in the study. 2. Cases who voluntarily withdrew consent from the study due to poor efficacy and inconvenience in follow-up. 3. cases lost to follow-up due to various reasons